Stock Market Impact: Exelixis shares traded at $50.48, near the 52‑week high of $52.96, reflecting investor confidence; eight analysts raised earnings forecasts; P/E 16.9 and PEG 0.41 indicate perceived undervaluation.
Listed Companies and Sectors: Exelixis Inc. (NASDAQ:EXEL) reported robust phase‑3 CABINET trial results, enhancing its oncology pipeline; a new collaboration with Merck for a phase‑3 colorectal cancer trial (STELLAR‑316) was announced, potentially benefiting the biotechnology and oncology sectors.
Investment Flows: The combination of a strong clinical read‑out and a Q1 2026 earnings beat (EPS $0.87 vs $0.77 expected, 12.99% surprise; revenue $611 M vs $608.95 M) may attract foreign portfolio investment into US biotech equities.
